Jeffrey L Cummings (Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV), a valued member of our editorial board for US Neurology, discusses how disease-modification is being approached for Alzheimer's disease and the important emerging role of monoclonal antibodies, which are being used to target various biological targets in Alzheimer's in clinical trials.
1. How is disease-modification being approached for Alzheimer’s disease (AD)? (0:12)
2. What role do monocloncal antibodies have in the treatment of AD? (0:43)
3. When in the course of AD should monocloncal antibodies be used? (1:32)
4. What are the biological targets of monocloncal antibodies? (2:47)
5. What are some of the promising monocloncal antibodies in trials now? (3:30)
6. What are the major challenges to developing monocloncal antibodies? (4:19)
Speaker disclosure: Jeffrey L Cummings has provided consultation to the following pharmaceutical companies: Acadia, Accera, Actinogen, ADAMAS, Alkahest, Allergan, Alzheon, Avanir, Axovant, Axsome, BiOasis Technologies, Biogen, Eisai, Genentech, Grifols, Kyowa, Lilly, Lundbeck, Merck, Nutricia, Otsuka, QR Pharma, Resverlogix, Roche, Samus, Servier, Suven, Takeda, Toyoma, and United Neuroscience companies. Dr Cummings has provided consultation to Neurocog, MedAvante, and Bracket assessment companies, as well as the Global Alzheimer Platform (GAP) foundation. Dr Cummings owns stocks in Cummings owns stocks in ADAMAS, Alzheon, BioAsis, EIP Pharma, Prana, Sonexa, MedAvante, Neurotrax, and QR Pharma. Dr Cummings owns the copyright of the Neuropsychiatric Inventory, and receives research support from Avid and Teva. NIH support: COBRE grant# P20GM109025; TRC-PAD # R01AG053798; DIAGNOSE CTE # U01NS093334.
Filmed during a video call with Jeffrey L Cummings from his office at the Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, US, May 2018.